Potential Vaccines and Post-Exposure Treatments for Filovirus Infections
Open Access
- 19 September 2012
- Vol. 4 (9) , 1619-1650
- https://doi.org/10.3390/v4091619
Abstract
Viruses of the family Filoviridae represent significant health risks as emerging infectious diseases as well as potentially engineered biothreats. While many research efforts have been published offering possibilities toward the mitigation of filoviral infection, there remain no sanctioned therapeutic or vaccine strategies. Current progress in the development of filovirus therapeutics and vaccines is outlined herein with respect to their current level of testing, evaluation, and proximity toward human implementation, specifically with regard to human clinical trials, nonhuman primate studies, small animal studies, and in vitro development. Contemporary methods of supportive care and previous treatment approaches for human patients are also discussed.Keywords
This publication has 175 references indexed in Scilit:
- Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated miceVaccine, 2011
- Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviationsArchiv für die gesamte Virusforschung, 2010
- Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody responseVaccine, 2010
- Inhibition of heat-shock protein 90 reduces Ebola virus replicationAntiviral Research, 2010
- Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenicVirology, 2010
- High‐level rapid production of full‐size monoclonal antibodies in plants by a single‐vector DNA replicon systemBiotechnology & Bioengineering, 2009
- Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against itCurrent Opinion in Structural Biology, 2009
- Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: Possible role of the prolonged half-life of the immunogenVaccine, 2008
- Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challengeVirology, 2008
- Protection against lethal challenge by Ebola virus-like particles produced in insect cellsVirology, 2008